TMCnet News
SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Salix Pharmaceuticals, Ltd. In Connection With The Proposed Sale Of The CompanySTEVENSON, Md. --(Business Wire)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the board of directors of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) relating to the proposed buyout of the Company. On July 8, 2014, Salix Pharmaceuticals, Ltd. ("Salix") and Cosmo Pharmaceuticals S.p.A. ("Cosmo") announced that they had entered into a definitive merger agreement pursuant to which Salix will combine with Cosmo Technologies Limited ("Cosmo Tech"), a subsidiary of Cosmo. Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc.
If you currently own common stock of Salix and would like to learn more about the investigation being conducted by Brower Piven, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.
|
